G Folprecht1, C Pericay2, M P Saunders3, A Thomas4, R Lopez Lopez5, J K Roh6, V Chistyakov7, T Höhler8, J-S Kim9, R-D Hofheinz10, S P Ackland11, D Swinson12, M Kopp13, D Udovitsa14, M Hall15, T Iveson16, A Vogel17, J R Zalcberg18. 1. Medical Department I, University Cancer Center, University Hospital Carl Gustav Carus, Dresden, Germany gunnar.folprecht@uniklinikum-dresden.de. 2. Hospital de Sabadell, Corporació Sanitaria Parc Taulí-Institut Universitari, Sabadell, Spain. 3. Department of Radiotherapy and Oncology, The Christie NHS Foundation Trust, Manchester. 4. Department of Cancer Studies, University of Leicester, Leicester, UK. 5. Department of Medical Oncology, Hospital Clinico Universitario e Instituto de Investigación, Santiago de Compostela, Spain. 6. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. 7. Pyatigorsk Cancer Dispensary, Stavropol, Russia. 8. Department I of Internal Medicine, Prosper Hospital, Recklinghausen, Germany. 9. Department of Oncology and Hematology, Korea University Guro Hospital, Seoul, Republic of Korea. 10. Department III of Internal Medicine, University Hospital, Mannheim, Germany. 11. Department of Medical Oncology, Calvary Mater Hospital, Newcastle Hunter Medical Research Institute and University of Newcastle, Callaghan, Australia. 12. Department of Oncology, St James' Hospital, Leeds, UK. 13. Samara Regional Oncology Dispensary, Samara. 14. Oncological Dispensary #2, Sochi, Russia. 15. Cancer Services Division, Mount Vernon Cancer Centre, Middlesex. 16. Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. 17. Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 18. School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
Abstract
BACKGROUND: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC. PATIENTS AND METHODS: Patients with mCRC were randomized to receive first-line therapy with mFOLFOX6 plus aflibercept (4 mg/kg) or mFOLFOX6 alone. The primary end point of this phase II study was the progression-free survival (PFS) rate at 12 months in each arm. The analysis of efficacy between the arms was a pre-planned secondary analysis. RESULTS: Of 236 randomized patients, 227 and 235 patients were evaluable for the primary efficacy analysis and safety, respectively. The probabilities of being progression-free at 12 months were 25.8% [95% confidence interval (CI) 17.2-34.4] for the aflibercept/mFOLFOX6 arm and 21.2% (95% CI 12.2-30.3) for the mFOLFOX6 arm. The median PFS was 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm and 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm; the hazard ratio of aflibercept/mFOLFOX6 versus mFOLFOX6 was 1.00 (95% CI 0.74-1.36). The response rates were 49.1% (95% CI 39.7-58.6) and 45.9% (95% CI 36.4-55.7) for patients treated with and without aflibercept, respectively. The most frequent treatment-emergent grade 3/4 adverse events (AEs) excluding laboratory abnormalities reported for aflibercept/mFOLFOX6 versus mFOLFOX6 were neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). Neutropenia grade 3/4 occurred in 36.1% versus 29.3%. The most common vascular endothelial growth factor inhibition class-effect grade 3/4 AEs for aflibercept/mFOLFOX6 versus mFOLFOX6 were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%) and pulmonary embolism (5.9% versus 5.2%). CONCLUSION: No difference in PFS rate was observed between treatment groups. Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity. CLINICAL TRIAL NUMBER: NCT00851084, www.clinicaltrials.gov, EudraCT 2008-004178-41.
RCT Entities:
BACKGROUND: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC. PATIENTS AND METHODS: Patients with mCRC were randomized to receive first-line therapy with mFOLFOX6 plus aflibercept (4 mg/kg) or mFOLFOX6 alone. The primary end point of this phase II study was the progression-free survival (PFS) rate at 12 months in each arm. The analysis of efficacy between the arms was a pre-planned secondary analysis. RESULTS: Of 236 randomized patients, 227 and 235 patients were evaluable for the primary efficacy analysis and safety, respectively. The probabilities of being progression-free at 12 months were 25.8% [95% confidence interval (CI) 17.2-34.4] for the aflibercept/mFOLFOX6 arm and 21.2% (95% CI 12.2-30.3) for the mFOLFOX6 arm. The median PFS was 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm and 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm; the hazard ratio of aflibercept/mFOLFOX6 versus mFOLFOX6 was 1.00 (95% CI 0.74-1.36). The response rates were 49.1% (95% CI 39.7-58.6) and 45.9% (95% CI 36.4-55.7) for patients treated with and without aflibercept, respectively. The most frequent treatment-emergent grade 3/4 adverse events (AEs) excluding laboratory abnormalities reported for aflibercept/mFOLFOX6 versus mFOLFOX6 were neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). Neutropenia grade 3/4 occurred in 36.1% versus 29.3%. The most common vascular endothelial growth factor inhibition class-effect grade 3/4 AEs for aflibercept/mFOLFOX6 versus mFOLFOX6 were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%) and pulmonary embolism (5.9% versus 5.2%). CONCLUSION: No difference in PFS rate was observed between treatment groups. Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity. CLINICAL TRIAL NUMBER: NCT00851084, www.clinicaltrials.gov, EudraCT 2008-004178-41.
Authors: James M Cleary; Nora K Horick; Nadine Jackson McCleary; Thomas A Abrams; Matthew B Yurgelun; Christopher G Azzoli; Douglas A Rubinson; Gabriel A Brooks; Jennifer A Chan; Lawrence S Blaszkowsky; Jeffrey W Clark; Lipika Goyal; Jeffrey A Meyerhardt; Kimmie Ng; Deborah Schrag; Diane M F Savarese; Christopher Graham; Bridget Fitzpatrick; Kathryn A Gibb; Yves Boucher; Dan G Duda; Rakesh K Jain; Charles S Fuchs; Peter C Enzinger Journal: Cancer Date: 2019-03-26 Impact factor: 6.860
Authors: Seung-Hoon Beom; Jong Gwang Kim; Seung Hyuk Baik; Seong Hoon Shin; Inkeun Park; Young Suk Park; Myung-Ah Lee; Soohyeon Lee; So-Yeon Jeon; Sae-Won Han; Myoung Hee Kang; Jisu Oh; Jin Soo Kim; Jin Young Kim; Mi Sun Ahn; Dae Young Zang; Byung-Noe Bae; Hong Jae Jo; Hee Kyung Kim; Jung-Han Kim; Ji Ae Yoon; Dong Han Kim Journal: J Cancer Res Clin Oncol Date: 2022-03-27 Impact factor: 4.553
Authors: Mauricio P Pinto; Paula Sotomayor; Gonzalo Carrasco-Avino; Alejandro H Corvalan; Gareth I Owen Journal: Int J Mol Sci Date: 2016-09-06 Impact factor: 5.923
Authors: Stefan Cristian Stanel; Jan Sjöberg; Tomas Salmonson; Paolo Foggi; Mariapaola Caleno; Daniela Melchiorri; Iordanis Gravanis; Kyriaki Tzogani; Francesco Pignatti Journal: ESMO Open Date: 2017-05-02